The global neuropathic pain treatment market is estimated to grow at a CAGR of nearly 5.8% during the forecast period. The demand for neurostimulation therapy for neuropathic pain management is expected to emerge owing to its significant potential in pain relief by interrupting the pain signals traveling between the brain and the spinal cord. Rising spinal cord injuries and diabetic neuropathy complications have led the demand for more potential and reliable pain management treatment, which in turn, will likely offer scope for neurostimulation therapy. As of 2019, the estimated number of individuals suffering from spinal cord injury in the US is nearly 291,000. Nearly 78% of new incidences were reported among males.
Neuropathic pain is the most common in patients suffering from spinal cord injury and usually difficult to treat. Spinal cord stimulation is an emerging technique that can be preferably used in interdisciplinary pain treatment. The main indications to use spinal cord stimulation include neuropathic pain conditions such as peripheral nerve injuries or complex regional pain syndrome (CRPS) or as well as mixed neuropathic conditions such as failed back surgery syndrome (FBSS). In spinal cord stimulation therapy, the electric pulses alter and mask the pain signals before they reach the brain.
It is a small device, like a pacemaker that delivers electrical pulses to the spinal cord and thereby supports people to effectively manage their chronic pain and decrease their use of opioid medications. It is considered as a safe, minimally invasive, and reversible treatment. However, further research is required to find out more evidence of the potential effects of spinal cord stimulation in neuropathy pain management, which may support to leverage the adoption of this therapy for the condition. The major companies in the field of neurostimulation include Abbott Laboratories, Boston Scientific Corp., and Medtronic plc.
These companies are focusing on developing neurostimulation devices to potentially manage neuropathic pain. For instance, in January 2017, Abbott Laboratories declared the introduction of the new Proclaim DRG neurostimulation system, which is developed to deliver dorsal root ganglion (DRG) stimulation to people with chronic neuropathic pain. The Proclaim DRG neurostimulation system delivers a more intuitive therapy experience to the patients coupled with the Proclaim platform’s Bluetooth wireless technology and iOS software. The Proclaim DRG neurostimulation system targets nerves within the DRG and thus, it has been clinically demonstrated to offer better pain relief than conventional spinal cord stimulation therapy as it directly targets the area of the body where pain occurs to improve quality of life.
The approval of Proclaim DRG neurostimulation system is offering access to this platform for the patients suffering from chronic neuropathic pain. The system features magnetic resonance (MR)-conditional recharge-free system that delivers better programming, increased battery capacity, and upgradeability. It also uses an iPod touch mobile digital device patient controller that provides wireless communication through Bluetooth wireless technology. Such kinds of innovations in neurostimulation devices will increase the reliability and efficacy of these devices for neuropathic pain treatment, which in turn, is expected to drive the global neuropathic pain treatment market.
To Request a Sample of our Report on Neuropathic Pain Treatment Market: https://www.omrglobal.com/request-sample/neuropathic-pain-treatment-market
Neuropathic Pain Treatment Market- Segmentation
By Indication
- Spinal Stenosis
- Diabetic Neuropathy
- Chemotherapy-Induced Peripheral Neuropathy
- Others
By Treatment
- Tricyclic Antidepressants
- Anticonvulsants
- Opioids
- Creams and Patches
- Steroids
- Others (Neurostimulation and Local Anesthesia)
A full Report of Neuropathic Pain Treatment Market is Available at: https://www.omrglobal.com/industry-reports/neuropathic-pain-treatment-market
Neuropathic Pain Treatment Market– Segment by Region
North America
- US
- Canada
Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Latin America
- Middle East and Africa
Company Profiles
- Abbott Laboratories
- Acorda Therapeutics, Inc.
- Assertio Therapeutics, Inc.
- Astellas Pharma Inc.
- AstraZeneca plc
- Biogen Inc.
- BioIntervene, Inc.
- Boston Scientific Corp.
- Cipla Ltd.
- Dr. Reddy’s Laboratories Ltd.
- Eli Lilly and Co.
- GlaxoSmithKline plc
- Glenmark Pharmaceuticals Ltd.
- Grünenthal GmbH
- Johnson & Johnson Services, Inc.
- Lexicon Pharmaceuticals, Inc.
- Lupin Ltd.
- Medtronic plc
- Pfizer Inc.
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
Reasons to Buy From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/neuropathic-pain-treatment-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
